Seeking Alpha

Assembly Biosciences, Inc. (ASMB) Discusses Positive Interim Results for ABI-1179 and ABI-5366 in Recurrent Genital Herpes Phase 1b Studies Transcript

Good evening, and welcome to the Assembly Bio conference call. [Operator Instructions] Please be advised that today's conference is being recorded and will be available for replay on the Assembly Bio ...
Reuters

Late valacyclovir for herpes yields greater response

NEW YORK (Reuters Health) - Therapy with valacyclovir (Valtrex, GlaxoSmithKline), started within three months of infection with either herpes simplex virus type 1 (HSV-1) or HSV type 2 (HSV-2), ...
Seeking Alpha

Assembly Biosciences Reports Positive Interim Phase 1a Results from Clinical Trial Evaluating Long-Acting Helicase-Primase Inhibitor ABI-1179 in Development for Recurrent ...

– ABI-1179 was well-tolerated, with a half-life of approximately four days and high exposure across the dose range evaluated supporting the potential for once-weekly oral administration at a low dose ...
Morningstar

Assembly Biosciences Reports Positive Interim Results from Phase 1b Clinical Study of Long-Acting Helicase-Primase Inhibitor Candidate ABI-5366 Showing Reductions in Viral ...

– 94% reduction in HSV-2 shedding rate and 98% reduction in high viral load shedding rate, both statistically significant, observed in cohort evaluating 350 mg weekly oral dose compared to placebo ...